Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, September 25, 2015 at 9:00

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

8,522 new share subscriptions based on the company's 2007C stock options approved by the Board of Directors of Revenio Group Corporation on September 17, 2015, have been entered into the trade register today. The share subscription price under 2007C option rights was 1.24 EUR per share. The subscription period for 2007C options is to June 1, 2016.

After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 7,943,811. These increases were recorded in their entirety in the unrestricted shareholders' equity fund.

Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on September 28, 2015.

Revenio Group Oyj
Olli-Pekka Salovaara
CEO

For further information, please contact:

President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology lies on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.